Insider Selling: Immunovant (NASDAQ:IMVT) Director Sells $192,000.00 in Stock

Immunovant, Inc. (NASDAQ:IMVT) Director Atul Pande sold 6,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $32.00, for a total transaction of $192,000.00. Following the completion of the transaction, the director directly owned 116,731 shares in the company, valued at approximately $3,735,392. This represents a 4.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunovant Trading Up 0.1%

Shares of IMVT stock opened at $34.15 on Friday. The company’s fifty day simple moving average is $26.82 and its 200-day simple moving average is $25.91. Immunovant, Inc. has a 52 week low of $13.79 and a 52 week high of $36.28. The company has a market cap of $7.01 billion, a PE ratio of -12.28 and a beta of 0.70.

Immunovant (NASDAQ:IMVT) last issued its earnings results on Wednesday, May 20th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.13). During the same quarter last year, the firm earned ($0.64) EPS. Equities research analysts expect that Immunovant, Inc. will post -2.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunovant

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Deep Track Capital LP increased its stake in Immunovant by 2.4% during the 3rd quarter. Deep Track Capital LP now owns 9,728,845 shares of the company’s stock worth $156,829,000 after buying an additional 228,845 shares during the period. Vanguard Group Inc. increased its stake in Immunovant by 14.0% during the 4th quarter. Vanguard Group Inc. now owns 7,779,314 shares of the company’s stock worth $197,750,000 after buying an additional 952,504 shares during the period. Armistice Capital LLC increased its stake in Immunovant by 12.2% during the 3rd quarter. Armistice Capital LLC now owns 5,836,000 shares of the company’s stock worth $94,076,000 after buying an additional 636,000 shares during the period. Morgan Stanley increased its stake in Immunovant by 147.4% during the 4th quarter. Morgan Stanley now owns 4,846,385 shares of the company’s stock worth $123,195,000 after buying an additional 2,887,359 shares during the period. Finally, State Street Corp increased its stake in Immunovant by 30.9% during the 4th quarter. State Street Corp now owns 3,786,926 shares of the company’s stock worth $96,264,000 after buying an additional 894,308 shares during the period. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on IMVT. Guggenheim raised their target price on shares of Immunovant from $41.00 to $44.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Bank of America raised their target price on shares of Immunovant from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday. Truist Financial lifted their price target on shares of Immunovant from $23.00 to $30.00 and gave the stock a “hold” rating in a research note on Friday. The Goldman Sachs Group lifted their price target on shares of Immunovant from $29.00 to $32.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a research note on Wednesday, April 8th. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $35.33.

Immunovant News Summary

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: Immunovant reported strong Week 16 data from its rheumatoid arthritis study of IMVT-1402, with response rates that investors viewed as supportive of the drug’s potential and the company’s broader autoimmune pipeline. Article Title
• Positive Sentiment: The company said its cutaneous lupus proof-of-concept trial is fully enrolled and expects topline results in the second half of 2026, giving shareholders another potential catalyst. Article Title
• Positive Sentiment: Immunovant highlighted about $902 million in cash at quarter-end, which should help fund development of IMVT-1402 and reduce near-term financing concerns. Article Title
• Neutral Sentiment: Truist raised its price target on IMVT to $30 from $23, but kept a Hold rating, suggesting analysts are acknowledging improved prospects while still seeing limited upside from current levels. Article Title
• Neutral Sentiment: The company posted a quarterly loss of $0.73 per share, wider than the $0.60 consensus estimate, though that earnings miss was largely overshadowed by the clinical update. Article Title
• Negative Sentiment: Director Atul Pande sold 6,000 shares in a pre-arranged 10b5-1 transaction, which may slightly temper sentiment even though the sale was planned in advance. Article Title

About Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.